Related Experiment Videos

Pediatric psoriasis: from immunogenetics to targeted therapies

Adriana Schikiera Martinelli Salathiel1, Elisa Nunes Secamilli1, Marina Gagheggi Maciel1

  • 1Department of Internal Medicine, Division of Dermatology, Pediatric Dermatology Outpatient Clinic, Hospital das Clínicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.

Anais Brasileiros De Dermatologia
|July 3, 2026
PubMed

Insights

Pediatric psoriasis management is updated with new immunogenetic and therapeutic advances. Despite limited evidence, especially in Brazil, biologic therapies show superior efficacy for children with psoriasis.

Area of Science:

  • Dermatology
  • Pediatrics
  • Immunology

Background:

  • Pediatric psoriasis causes significant life course impairment.
  • Limited evidence exists for pediatric psoriasis compared to adult cases.

Purpose of the Study:

  • Update pediatric psoriasis management integrating recent advances.
  • Highlight challenges in diagnosis and treatment, particularly in Brazil.

Main Methods:

  • Narrative review of studies from 2009-2025.
  • Searched PubMed, Cochrane Library, SciELO using keywords: psoriasis, child health, pediatrics, therapeutics, comorbidity, T-lymphocyte antigen differentiation.

Main Results:

  • Chronic plaque is the most common presentation.
  • Differential diagnoses include atopic dermatitis and autoimmune diseases.
  • Biologic therapies offer superior efficacy and safety over conventional treatments for pediatric psoriasis.

Conclusions:

  • Scarcity of pediatric psoriasis guidelines necessitates further research.
  • Expanding knowledge is crucial for improving diagnosis, treatment, and access to therapies in pediatric psoriasis.
Abstract

Keywords:
AntigensChild healthComorbidityDifferentiationPediatricsPsoriasisT-LymphocyteTherapeutics

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...